ATE319472T1 - Verfahren zur behandlung der gefässerkrankungen mit aktiviertem protein c - Google Patents

Verfahren zur behandlung der gefässerkrankungen mit aktiviertem protein c

Info

Publication number
ATE319472T1
ATE319472T1 AT98302165T AT98302165T ATE319472T1 AT E319472 T1 ATE319472 T1 AT E319472T1 AT 98302165 T AT98302165 T AT 98302165T AT 98302165 T AT98302165 T AT 98302165T AT E319472 T1 ATE319472 T1 AT E319472T1
Authority
AT
Austria
Prior art keywords
activated protein
vascular diseases
treating vascular
treating
medicament
Prior art date
Application number
AT98302165T
Other languages
English (en)
Inventor
Brian William Grinnell
Daniel Charles Howey
Jackson Charles Van
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Application granted granted Critical
Publication of ATE319472T1 publication Critical patent/ATE319472T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6464—Protein C (3.4.21.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21069—Protein C activated (3.4.21.69)
AT98302165T 1997-03-24 1998-03-24 Verfahren zur behandlung der gefässerkrankungen mit aktiviertem protein c ATE319472T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US4253397P 1997-03-24 1997-03-24
US6254997P 1997-10-20 1997-10-20
US6476597P 1997-11-07 1997-11-07

Publications (1)

Publication Number Publication Date
ATE319472T1 true ATE319472T1 (de) 2006-03-15

Family

ID=27366150

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98302165T ATE319472T1 (de) 1997-03-24 1998-03-24 Verfahren zur behandlung der gefässerkrankungen mit aktiviertem protein c

Country Status (19)

Country Link
EP (1) EP0872245B1 (de)
JP (1) JP4680329B2 (de)
KR (1) KR20010005626A (de)
CN (1) CN1168492C (de)
AT (1) ATE319472T1 (de)
AU (1) AU733756B2 (de)
BR (1) BR9808063A (de)
CA (1) CA2284279A1 (de)
DE (1) DE69833727T2 (de)
EA (1) EA199900862A1 (de)
ES (1) ES2257794T3 (de)
ID (1) ID23176A (de)
IL (1) IL131615A0 (de)
NO (1) NO994630D0 (de)
NZ (1) NZ337291A (de)
PL (1) PL335802A1 (de)
TR (1) TR199902335T2 (de)
TW (1) TW513307B (de)
WO (1) WO1998042358A1 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1326355A (zh) * 1998-11-13 2001-12-12 伊莱利利公司 治疗肝素诱导的血小板减少症的方法
ATE504310T1 (de) * 2000-02-04 2011-04-15 Scripps Research Inst Neuroprotektive, antithrombotische und anti- entzündliche anwendungen von aktiviertem protein c
EP1567199B1 (de) * 2002-12-05 2014-07-23 Zz Biotech L.L.C. Neuroprotektive wirkung von aktiviertem protein c ist unabhängig von seiner gerinnungshemmenden wirkung
CN100451033C (zh) * 2005-01-11 2009-01-14 北京诺赛基因组研究中心有限公司 抑制人体转录因子ap-1的基因及其编码多肽和用途
CN108159399B (zh) * 2017-12-29 2020-07-24 华中科技大学同济医学院附属同济医院 一种凝血蛋白酶aPC在防治糖尿病心肌病药物中的应用
US11217526B2 (en) 2019-02-28 2022-01-04 Taiwan Semiconductor Manufacturing Co., Ltd. Semiconductor device with source resistor and manufacturing method thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5516650A (en) * 1985-06-27 1996-05-14 Zymogenetics, Inc. Production of activated protein C
US5084274A (en) * 1987-11-17 1992-01-28 Scripps Clinic And Research Foundation Inhibition of arterial thrombotic occlusion or thromboembolism
GB8819607D0 (en) * 1988-08-17 1988-09-21 Wellcome Found Novel combination
US5254532A (en) * 1989-06-26 1993-10-19 Immuno Aktiengesellschaft Fur Chemisch-Medizinische Produkte Preparation for treating and preventing thromboses and thromboembolic complications, use of such a preparation and a method of producing the same
JP2886061B2 (ja) * 1993-10-29 1999-04-26 財団法人化学及血清療法研究所 プロテインｃもしくは活性化プロテインｃの安定化方法及び安定化組成物

Also Published As

Publication number Publication date
EP0872245B1 (de) 2006-03-08
AU6474198A (en) 1998-10-20
CN1168492C (zh) 2004-09-29
KR20010005626A (ko) 2001-01-15
AU733756B2 (en) 2001-05-24
BR9808063A (pt) 2000-06-06
EA199900862A1 (ru) 2000-04-24
NO994630L (no) 1999-09-23
JP4680329B2 (ja) 2011-05-11
WO1998042358A1 (en) 1998-10-01
CN1252726A (zh) 2000-05-10
CA2284279A1 (en) 1998-10-01
IL131615A0 (en) 2001-01-28
DE69833727T2 (de) 2006-08-31
NO994630D0 (no) 1999-09-23
TW513307B (en) 2002-12-11
ID23176A (id) 2000-03-23
EP0872245A1 (de) 1998-10-21
ES2257794T3 (es) 2006-08-01
PL335802A1 (en) 2000-05-22
TR199902335T2 (xx) 2000-01-21
NZ337291A (en) 2001-05-25
DE69833727D1 (de) 2006-05-04
JP2001518933A (ja) 2001-10-16

Similar Documents

Publication Publication Date Title
DE69428130T2 (de) Verwendung von bcl-2 zur herstellung von arzneimitteln zur therapeutischen behandlung und verhinderung von krankheiten
ATE280577T1 (de) Oxa-säuren und verwandte verbindungen zur behandlung von störungen der haut
DE69739792D1 (de) Verfahren zur Behandlung von Augenerkrankungen
DE69435243D1 (de) Verwendung vom neurotoxischem Komponent von Botulinum Toxin zur Behandlung von Glattmuskelkrankheiten
DE69734284D1 (de) Zusammensetzung eines polynukleotidvakzins zur behandlung von atemwegs- und fortpflanzungsbezogenen erkrankungen des schweins
NZ504026A (en) Methods for treating hypercoagulable states or acquired protein C deficiency using human-activated protein C
DE69230046T2 (de) 2-Bromomelatonin zur Behandlung von Schlafstörungen
ATE195527T1 (de) Neue steroidester zur behandlung von hauterkrankungen
DE58902094D1 (de) Kombinationspraeparat zur behandlung von nervenzell-und nervenfasererkrankungen und verletzungen.
ATE99932T1 (de) Verwendung von pyrrolicloncarbonsaeurealkylestern zur herstellung eines arzneimittels zur behandlung von ichtyosis.
ATE137965T1 (de) Verwendung von tomoxetine zur behandlung von funktionsstörungen der niedrigen harnwege
DE69532066D1 (de) Arzneimittel zur Behandlung von Restenosis und Gefässsklerose
ATE319472T1 (de) Verfahren zur behandlung der gefässerkrankungen mit aktiviertem protein c
DE69225754D1 (de) Verfahren zur Behandlung von wasserunlöslichen Superabsorbensmaterialien
DE69431199D1 (de) Melatonin-Derivate zur Verwendung in der Behandlung von Schlafstörungen
ATE239470T1 (de) Melatonin-derivate zur verwendung in der behandlung von desynchronisierungs-erkankungen
DE69307702T2 (de) Verwendung von (e) - 2 - (p -fluorophenethyl)- 3 - fluoroallylamine zur behandlung der alzheimerschen krankheit
DE3878529D1 (de) Vorrichtung zur behandlung von verstauchungen, insbesondere der sprunggelenke sowie zur vermeidung von dabei auftretenden bestimmten komplikationen.
ATE201993T1 (de) Verwendung von olanzapine zur herstellung eines arzneimittels zur behandlung der zerebralen fokalen ischämie
DE69430807D1 (de) Verfahren zur behandlung von lebererkrankungen und ähnlichen indikationen mit vasodilatierenden wirkstoffen
DE69133542D1 (de) Katheter zur Behandlung von Prostaterkrankungen
ATE85750T1 (de) Vorrichtung zur behandlung von verstauchungen, insbesondere der sprunggelenke sowie zur vermeidung von dabei auftretenden bestimmten komplikationen.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties